Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by an educational grant from Exelixis, Inc.

Community Practice Connections™: Show Me the Data™: Decision-Making in mRCC When There Are Many Options

Release Date: April 6, 2021
Expiration Date: April 6, 2022

Activity Overview

A total of 73,750 patients will be diagnosed with renal cell carcinoma (RCC) this year, and approximately 14,830 patients will die from these tumors. Before the advent of targeted therapies, the treatment for patients with metastatic RCC (mRCC) had remained largely unchanged for decades and relied on cytokine therapy to prevent disease progression. However, these therapies were associated with treatment-limiting toxicities, low response rates, and short survival benefits. Management strategies for RCC have evolved with the emergence of new data for novel combinations and emerging novel therapeutic approaches.

This Community Practice Connection™ program provides an in-depth review of some of the key highlights from virtual symposium held at the 2021 ASCO Genitourinary (GU) Symposium in February 2021. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects of managing patients with RCC, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Exelixis, Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational program is directed toward medical oncologists interested in the treatment of renal cell carcinoma. Nurse practitioners, physician assistants, nurses, and other health care professionals involved in the treatment and management of patients with renal cell carcinoma are also invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Identify key aspects of RCC pathobiology and how increased understanding of biology applies to therapeutic development
  • Evaluate recently reported clinical trial data likely to impact treatment options across lines of care for RCC
  • Integrate evidence-based treatment options into clinical scenarios in RCC
  • Assess strategies to monitor, mitigate, and prevent treatment-related adverse events associated with single-agent and combination strategies in RCC

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.


Robert A. Figlin, MD, FACP
Robert A. Figlin, MD, FACP
Steven Spielberg Family Chair in Hematology Oncology
Professor of Medicine and Biomedical Sciences
Deputy Director, Cedars-Sinai Cancer
Deputy Director, Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Los Angeles, California

Disclosures: Grant/Research Support: Bristol Myers Squibb, Calithera Biosciences, Exelixis, Inc., Merck, Pfizer; Consultant: Apollomics, Inc., Arrowhead Pharmaceuticals, Aveo Oncology, Bristol Myers Squibb, Eisai, Exelixis, Inc., Merck.

Rana R. McKay, MD
Rana R. McKay, MD
Associate Professor of Medicine and Urology
UC San Diego School of Medicine
La Jolla, California

Disclosures: Grant/Research Support: Bayer, Pfizer, Tempus; Consultant: Dendreon, Vividion Therapeutics; Speakers’ Bureau: AstraZeneca, Bayer, Bristol Myers Squibb, Calithera Biosciences, Dendreon, Exelixis, Inc., Janssen, Merck, Novartis, Pfizer, Sanofi, Tempus.

Sumanta K. Pal, MD
Sumanta K. Pal, MD
Clinical Professor
Department of Medical Oncology & Experimental Therapeutics
City of Hope Comprehensive Cancer Center
Chair, SWOG Renal Cancer Center Translational Medicine
Duarte, California

Disclosures: Sumanta K. Pal has no relevant financial relationships with ineligible companies.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By